[Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].
In the era of personalized medicine, targeted cancer treatments aim to improve therapy and overall survival. Specific therapies are individually customized for patients based on molecular alterations of the neoplastic cells. The pathologist has a central role in the identification and characterization of a variety of molecular markers that can be used to better predict outcome and assess therapeutic success of specific targeted approaches.
Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen und Comprehensive Cancer Center, Eberhard-Karls-Universität, Liebermeisterstr. 8, 72076, Tübingen, Deutschland, irina.bonzheim@med.uni-tuebingen.de.
I
I
Bonzheim
F
F
Fend
D014408:Biomarkers, Tumor / Q000235:genetics*; D004252:DNA Mutational Analysis; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D057285:Precision Medicine; D011379:Prognosis; D015398:Signal Transduction / Q000235:genetics*
D014408:Biomarkers, Tumor; D005819:Genetic Markers